Scholar Rock upgraded by Jefferies with a new price target
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies upgraded Scholar Rock from Hold to Buy and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | $55.00 | Buy | Citigroup |
| 11/18/2025 | $42.00 | Outperform | Wolfe Research |
| 10/9/2025 | $53.00 | Buy | BofA Securities |
| 9/17/2025 | $45.00 | Overweight | Barclays |
| 9/15/2025 | $51.00 | Outperform | Leerink Partners |
| 8/21/2025 | $50.00 | Buy | Jefferies |
| 7/30/2025 | $53.00 | Strong Buy | Raymond James |
| 7/17/2025 | Overweight | Cantor Fitzgerald |
Citigroup initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $55.00
Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00
BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00
SCHEDULE 13G - Scholar Rock Holding Corp (0001727196) (Subject)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:
Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us
Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co
Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:50 p.m. ET on Wednesday, March 4, 2026 in Boston, MA Leerink Partners 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 2:
Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is us
Scholar Rock (NASDAQ:SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to "Events and Presentations" in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call. An archived replay of the webcast will be available on the Company's
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)